Coeptis Therapeutics Holdings, Inc.
For the period ended Dec 31, 2025. Filed Mar 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 19, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 14. Principal Accountant Fees and Services
| ITEM 14. | PRINCIPAL ACCOUNTANT FEES AND SERVICES |
|---|
The following table shows the fees paid or accrued for the audit and other services provided by Astra Audit & Advisory, LLC and Tuner, Stone & Company, LLP, our independent registered public accounting firms for the years ended December 31, 2025 and 2024, respectively.
| 12-31-2025 | 12-31-2024 | |||
| Audit fees | $91,820 | $159,335 | ||
|---|---|---|---|---|
| Other service fees | 94,000 | 22,949 | ||
| Total | $185,820 | $182,284 |
Audit fees consist of fees billed for services rendered for the audit of our consolidated financial statements included in this Annual Report on Form 10–K, and reviews of our quarterly condensed consolidated financial statements included in the Company’s quarterly filings on Form 10-Q.
Other service fees consist of fees reasonably related to the performance of the audit or review of the Company’s consolidated financial statements that are not reported as “Audit fees”, and other miscellaneous items.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.